ABIOMED, Inc. (NASDAQ:ABMD) – William Blair lifted their Q2 2019 earnings per share estimates for ABIOMED in a note issued to investors on Thursday, Zacks Investment Research reports. William Blair analyst M. Kaczor now anticipates that the medical equipment provider will post earnings per share of $0.66 for the quarter, up from their prior estimate of $0.64. William Blair also issued estimates for ABIOMED’s Q4 2019 earnings at $0.78 EPS and FY2020 earnings at $4.18 EPS.
ABIOMED (NASDAQ:ABMD) last posted its quarterly earnings results on Thursday, February 1st. The medical equipment provider reported $0.70 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.50 by $0.20. The firm had revenue of $154.00 million for the quarter, compared to analyst estimates of $154.00 million. ABIOMED had a return on equity of 15.54% and a net margin of 16.58%. The business’s quarterly revenue was up 34.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.34 EPS.
ABMD has been the topic of several other research reports. Zacks Investment Research raised ABIOMED from a “hold” rating to a “buy” rating and set a $220.00 price target on the stock in a research report on Tuesday, November 7th. BTIG Research reaffirmed a “hold” rating on shares of ABIOMED in a research report on Sunday, February 4th. BidaskClub raised ABIOMED from a “hold” rating to a “buy” rating in a report on Thursday, January 11th. Piper Jaffray Companies reissued a “positive” rating and set a $300.00 target price (up from $220.00) on shares of ABIOMED in a report on Thursday, February 1st. Finally, Leerink Swann boosted their target price on ABIOMED from $200.00 to $265.00 and gave the stock an “outperform” rating in a report on Friday, January 19th. Three equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $263.86.
ABIOMED (ABMD) traded up $0.27 during trading hours on Monday, hitting $233.99. The company’s stock had a trading volume of 313,800 shares, compared to its average volume of 402,732. The firm has a market cap of $11,070.00, a price-to-earnings ratio of 126.43, a price-to-earnings-growth ratio of 3.10 and a beta of 0.36. ABIOMED has a 52-week low of $108.21 and a 52-week high of $255.42.
Hedge funds have recently bought and sold shares of the stock. JPMorgan Chase & Co. boosted its stake in ABIOMED by 5.1% in the 2nd quarter. JPMorgan Chase & Co. now owns 14,094 shares of the medical equipment provider’s stock valued at $2,019,000 after purchasing an additional 680 shares during the period. Wells Fargo & Company MN boosted its stake in ABIOMED by 9.0% in the 2nd quarter. Wells Fargo & Company MN now owns 15,712 shares of the medical equipment provider’s stock valued at $2,252,000 after purchasing an additional 1,297 shares during the period. Teachers Advisors LLC boosted its stake in ABIOMED by 7.2% in the 2nd quarter. Teachers Advisors LLC now owns 46,706 shares of the medical equipment provider’s stock valued at $6,693,000 after purchasing an additional 3,118 shares during the period. FMR LLC bought a new stake in ABIOMED in the 2nd quarter valued at $32,609,000. Finally, Parametric Portfolio Associates LLC boosted its stake in ABIOMED by 1.2% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 43,532 shares of the medical equipment provider’s stock valued at $6,238,000 after purchasing an additional 531 shares during the period. 90.35% of the stock is currently owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION NOTICE: “ABIOMED, Inc. (ABMD) Forecasted to Post Q2 2019 Earnings of $0.66 Per Share” was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this story on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The original version of this story can be read at https://www.dispatchtribunal.com/2018/02/14/q2-2019-eps-estimates-for-abiomed-inc-lifted-by-analyst-abmd.html.
ABIOMED Company Profile
ABIOMED, Inc is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart.
Get a free copy of the Zacks research report on ABIOMED (ABMD)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ABIOMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED and related companies with MarketBeat.com's FREE daily email newsletter.